{"title":"Favipiravir: An Antiviral Drug","authors":"Ganesh R. Bharskar, Pratik Malvade","doi":"10.52711/2349-2988.2022.00041","DOIUrl":null,"url":null,"abstract":"Favipiravir is an antiviral drug that has been shown to treat a variety of life-threatening infections, including Ebola, Lassa, and the COVID-19 virus. It's a pyrazine carboxamide derivative with antiviral action that targets RNA-dependent RNA polymerase enzymes, which are required for viral genome transcription and replication. Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19. The nucleoside analogue favipiravir is rapidly metabolized in host cells which disrupts viral synthesis and leads to mutagenesis The mechanism of action of the Favipiravir and Side effects like QTc prolongation or teratogenicity pose risk to extensive community application discusses in this review. In this article, we have tried to provide a comprehensive, evidence-based review of this drug about synthesis, Pharmacology, Mechanism of Action, Antiviral activity, Consequences.","PeriodicalId":20963,"journal":{"name":"Research Journal of Pharmaceutical Dosage Forms and Technology","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmaceutical Dosage Forms and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/2349-2988.2022.00041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Favipiravir is an antiviral drug that has been shown to treat a variety of life-threatening infections, including Ebola, Lassa, and the COVID-19 virus. It's a pyrazine carboxamide derivative with antiviral action that targets RNA-dependent RNA polymerase enzymes, which are required for viral genome transcription and replication. Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19. The nucleoside analogue favipiravir is rapidly metabolized in host cells which disrupts viral synthesis and leads to mutagenesis The mechanism of action of the Favipiravir and Side effects like QTc prolongation or teratogenicity pose risk to extensive community application discusses in this review. In this article, we have tried to provide a comprehensive, evidence-based review of this drug about synthesis, Pharmacology, Mechanism of Action, Antiviral activity, Consequences.